The role of Platinum(IV)-based antitumor drugs and the anticancer immune response in medicinal inorganic chemistry. A systematic review from 2017 to 2022

Exploring a Mitochondria Targeting, Dinuclear Cyclometalated Iridium (III) Complex for Image-Guided Photodynamic Therapy in Triple-Negative Breast Cancer Cells

“…12−16 Even though the success of cisplatin as an anticancer agent has ignited a pursuit for the development of several inorganic anticancer drugs, they generally induce cell death via the oxygen-independent type III pathway and are referred as photoactivated chemotherapeutic (PACT) agents rather than as PDT agents. 10,17,18 Despite numerous reported examples of Pt(II) complexes as efficient singlet oxygen sensitizers, only a few platinum complexes have demonstrated photosensitizing effects via a type I or type II mechanism. 10 Subsequently, it was found that iridium(III) complexes act as efficient photosensitizers through a type I or type II mechanism and are suitable for live-cell imaging-guided PDT applications.…”

“…Recently, cyclometalated transition-metal complexes, particularly Pt­(II) and Ir­(III), have gained widespread attention due to their impressive luminescent properties and for their performance as a highly effective class of singlet oxygen photosensitizers. − Even though the success of cisplatin as an anticancer agent has ignited a pursuit for the development of several inorganic anticancer drugs, they generally induce cell death via the oxygen-independent type III pathway and are referred as photoactivated chemotherapeutic (PACT) agents rather than as PDT agents. ,, Despite numerous reported examples of Pt­(II) complexes as efficient singlet oxygen sensitizers, only a few platinum complexes have demonstrated photosensitizing effects via a type I or type II mechanism . Subsequently, it was found that iridium­(III) complexes act as efficient photosensitizers through a type I or type II mechanism and are suitable for live-cell imaging-guided PDT applications. , In addition, iridium complexes show excellent photophysical and photochemical properties, such as a large Stokes shift, ease in color tuning, high triplet and singlet oxygen quantum yield, long luminescence lifetimes, and high chemical and photochemical stabilities. , …”

Synthesis, characterization, andin vivoevaluation of the anticancer activity of a series of 5- and 6-(halomethyl)-2,2′-bipyridine rhenium tricarbonyl complexes

“…The discovery of cisplatin, however, ignited a thriving field of research, with several medicinal inorganic chemists now exploring the potential anticancer efficacy of other transition metal species. Classic platinum( ii ) and new platinum( iv ) complexes still dominate the literature 2 with ruthenium, copper and gold being other prominent examples. 3–5 Rhenium( i ) tricarbonyl complexes are amongst the least explored in the field, but in the last decade have gained significant attention due to their unique and promising properties, which include high stability, low toxicity and rich spectroscopic and luminescent features.…”

Cancer cell membrane fused liposomal platinum(iv) prodrugs overcome cisplatin resistance in esophageal squamous cell carcinoma chemotherapy

“…To address CDDP resistance, Pt( iv ) prodrugs have been developed, presenting a less toxic alternative. 12–16 Owing to the fully saturated center Pt atom, Pt( iv ) prodrugs are more resistant to ligand substitution reactions than CDDP, allowing minimized undesired reactions with biomolecules before binding to DNA. 11,17 Within tumor cells, Pt( iv ) prodrugs can be reduced, predominantly by agents like GSH, to yield their highly cytotoxic Pt( ii ) counterparts.…”